In early-stage non-small cell lung cancer (NSCLC), post-treatment mortality may influence the comparative effectiveness of surgery and stereotactic body radiotherapy (SBRT), with implications for shared decision making among high-risk surgical candidates. We analyzed early mortality after these interventions using the National Cancer Database.
INTRODUCTION
Although an anatomic lung resection represents the standard curative-intent therapy for patients with early-stage non-small-cell lung cancer (NSCLC), stereotactic body radiotherapy (SBRT) has emerged as the preferred management strategy for those who are not operative candidates. [1] [2] [3] Several randomized trials comparing surgery with SBRT for operable early-stage NSCLC have been launched, but most have closed early because of poor accrual. In the single available comparison of randomized data, the finding of improved 3-year survival with SBRT over surgery 4 is provocative; however, this analysis was limited by factors including the pooling of data from two separate trials, small patient numbers, and low utilization rates of minimally invasive surgical techniques. Nevertheless, the results of this analysis underscore the importance of achieving a better understanding of the differences in outcomes between these two modalities.
One area that warrants further investigation is the potential difference in posttreatment mortality between surgery and SBRT.
Institutional data have characterized noncancer
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deaths as the leading cause of mortality in the first 18 months after surgery for early-stage NSCLC across all ages and in the first 30 months among patients older than 75 years of age. 5 In addition, population-based and prospective analyses comparing surgery and SBRT have depicted early survival curve separation in favor of SBRT, 4, [6] [7] [8] [9] which raises the possibility of excess noncancer deaths among surgical patients. However, dedicated analyses comparing post-treatment mortality between surgery and SBRT are limited. This presents a barrier to shared decision making between patients and providers and highlights the need for additional data to guide nuanced treatment decisions in patients with early-stage NSCLC who may be at an increased risk of treatment-related mortality. In this analysis, we characterize differences in post-treatment mortality between surgery and SBRT and explore the effect of age on mortality in a large contemporary cohort in the United States.
PATIENTS AND METHODS
The National Cancer Database (NCDB), a joint project of the Commission on Cancer (CoC) of the American College of Surgeons (ACS) and the American Cancer Society, is a hospital-based registry that captures approximately 70% of incident cancer cases in the United States and collects data from . 1,500 CoC-accredited cancer programs. The NCDB contains detailed information on demographic, clinical, and treatment-related factors. The ACS and the CoC have not verified and are not responsible for the analytic or statistical methodology used or for the conclusions drawn from these data by the investigators. This study was performed with the approval of our local institutional review board.
The NCDB was queried for patients diagnosed with NSCLC between 2004 and 2013 (Appendix Fig A1, online only) . We excluded 236,326 patients with prior diagnoses of malignancy and 76,963 who received all of their treatment at a non-CoC-accredited facility. After we removed an additional 598,747 patients with clinical stage other than T1 to T2aN0M0 and 2,188 who received no local therapy, our cohort was reduced to 88,676 patients undergoing surgery and 10,380 undergoing SBRT. After excluding 12,053 patients undergoing surgery and 2,164 patients undergoing SBRT who were missing information on the timing of treatment or follow-up, our analytic cohort comprised 76,623 patients undergoing surgery and 8,216 patients undergoing SBRT. Because the focus of this analysis was short-term post-treatment mortality, patients with a clinical diagnosis of NSCLC without biopsy were included in the SBRT cohort (5.4%). Of note, the American Joint Commission on Cancer staging system changed its definitions of T1 and T2 disease in 2010. As a result, for patients diagnosed in 2009 and earlier, we used the tumor size variable, when available, to reassign patients as T1a, T1b, or T2a to match post-2010 staging criteria.
Patients were stratified into seven groups by 5-year windows of age at diagnosis (# 55, 56 to 60, 61 to 65, 66 to 70, 71 to 75, 76 to 80, and $ 81 years of age). Patients undergoing surgery were categorized as receiving sublobar resection, lobectomy, or pneumonectomy. For each patient, time from diagnosis to treatment initiation was subtracted from total duration of follow-up to calculate post-treatment follow-up time.
Statistical analyses were performed using SPSS Version 24.0 (SPSS, Chicago, IL) and SAS Version 9.4 (SAS Institute, Cary, NC). Covariates were selected a priori and included age group, year of diagnosis, sex, race, insurance status, income quartile (zip code level), facility type, facility volume quartile, comorbidity, lobar subsite, T classification, histology, and intervention. Pearson's x 2 tests were used to assess associations between treatment modalities and absolute mortality rates. Univariate and multivariate Cox regression models, with censoring at 30 and 90 days, were used to assess the association between mortality and demographic, facilityspecific, clinical, and treatment factors, with the results reported as hazard ratios (HRs) for mortality with corresponding 95% CIs. Tests were twosided, with a 0.05 level of significance. Propensity score matching (PSM) was performed incorporating the aforementioned variables. Scores were calculated using logistic regression to estimate the probability of receiving SBRT. Three-to-one (surgery:SBRT) matching without replacement was performed using a caliper-match algorithm, 10 with the caliper width set to 0.05 times the standard deviation of the logit of the propensity score. 11 The quality of matching was assessed by comparing standardized differences between the treatment groups, 12,13 with a threshold of , 0.1 indicating good balance between groups.
14 We then used a marginal Cox proportional hazards model with a robust variance estimator to account for correlation within the matched pairs.
RESULTS
There were significant baseline differences between the surgery and SBRT groups. Factors associated with an increasing utilization of surgery included younger age, earlier years of diagnosis, and private insurance; surgery was also increased in higher income areas, non-academic facilities, and facilities with lower patient volume. Patients undergoing surgery were also more likely to have T2 tumors, right-sided tumors, and adenocarcinoma histology ( Table 1) . Lobectomy was the most common surgical approach (77.7%), followed by sublobar resection (20.3%) and pneumonectomy (2.0%). The most common SBRT fractionation schedules used were 50 Gy in five fractions (19.3%), 60 Gy in three fractions (17.7%), 48 Gy in four fractions (17.0%), and 54 Gy in three fractions (14.0%).
Absolute rates of 30-day and 90-day mortality for the overall population and for each age group are listed in Tables 2 and 3 , respectively, and the cumulative incidence of post-treatment mortality over time is displayed in Figure 1 . In the entire cohort of 84,839 patients, 30-day and 90-day mortality rates were lower among those receiving SBRT (0.73% and 2.93%) compared to those undergoing any surgery (2.07% and 3.59%), sublobar resection (1.77% and 3.27%), lobectomy (2.00% and 3.46%), or pneumonectomy (7.82% and 11.86%; Tables 2 and 3 ; Fig 2A) . The absolute differences (D) in mortality between SBRT and any surgery at 30 and 90 days were 1.34% (P , .001) and 0.66% (P , .001), respectively.
Across age groups, excess mortality after surgery versus SBRT tended to increase as a function of age, particularly for patients older than 70 years of age (Figs 2A and 2B ). For patients 71 to 75 years of age, 30-day mortality rates for surgery and SBRT, respectively, were 2.51% versus 0.64% (D, 1.87%), and 90-day rates were 4.46% versus 2.44% (D, 2.02%; Fig 1F) . For patients 76 to 80 years of age, 30-day rates were 3.56% versus 0.76% (D, 2.80%) and the 90-day rates were 5.85% versus 3.26% (D, 2.59%; Fig 1G) . For patients older than 80 years, the 30-day rates were 3.94% versus 0.91% (D, 3.03%) and the 90-day rates were 7.30% versus 3.63% (D, 3.67%; Fig 1H) . Mortality rates were significantly higher after surgery compared to SBRT for each age subgroup, with the exceptions of 30-day rates in the youngest subgroup (# 55 years) and 90-day rates among the youngest three subgroups (# 55 years of age, 56 to 60 years of age, and 61 to 65 years of age).
Subset analyses by age group of the HR with corresponding 95% CI for mortality at 30 and 90 days after treatment are depicted in Figures 3A and 3B , respectively. The interactions between age and mortality by intervention were significant at both 30 days (interaction P = .027) and 90 days (interaction P , .001), with progressively higher HRs for mortality with surgery versus SBRT observed with increasing age. On multivariate Cox regression analysis (MVA), older age at diagnosis, Charlson-Deyo comorbidity score $ 2, tumor location in the right upper lobe or right lower lobe, T1b classification, and squamous cell histology were each associated with increased hazard of 30-day mortality. Earlier year of diagnosis, female sex, private insurance, higher income quartile, academic facility type, higher facility volume, and tumor location in the right middle lobe were each associated with reduced mortality hazard (Table 4) . Similarly, factors associated with increased hazard of 90-day mortality included older age at diagnosis, comorbidity score $ 2, tumor location in the right upper lobe or right lower lobe, T classification other than T1a, and squamous cell histology. Predictors of reduced 90-day mortality hazard included earlier year of diagnosis, female sex, private insurance, higher income quartile, academic facility type, and higher facility volume (Table 4) .
On MVA, all surgical approaches were associated with increased mortality compared to SBRT, and the HRs for mortality were progressively higher with an increasing extent of surgical resection at both 30 days (sublobar resection HR, 2.85; 95% CI, 2.14 to 3.79; lobectomy HR, 3.65; 95% CI, 2.80 to 4.76; pneumonectomy HR, 14.5; 95% CI, 10.3 to 20.2; all P , .001) and 90 days post-treatment (sublobar resection HR, 1.37; 95% CI, 1.17 to 1.61; lobectomy HR, 1.60; 95% CI, 1.39 to 1.84; pneumonectomy HR, 5.66; 95% CI, 4.53 to 7.05; all P , .001; Table 4 ).
For the PSM cohort, 3:1 matching yielded absolute standardized differences of , 0.1 for each variable, indicating good balance between the 20,400 patients undergoing surgery and 6,800 patients undergoing SBRT (Appendix Table A1 , online only). Mortality rates in this cohort were significantly higher at both 30 and 90 days after surgery (2.41% and 4.23%) than after SBRT (0.79% and 2.82%; Appendix Fig A2, online only) . The HR for 30-day mortality was 3.06 (95% CI, 2.31 to 4.06; P , .001), favoring SBRT. The HR for 90-day mortality was 1.52 (95% CI, 1.30 to 1.78; P , .001), also favored SBRT. place an increasing emphasis on shared decision-making discussions that acknowledge the varying risk profiles and outcomes with surgery and SBRT in early-stage NSCLC. In addition to considerations regarding logistics, toxicity, and oncologic outcomes, information regarding post-treatment morbidity and mortality represents an important component of shared decision making. 16 Indeed, research into patient preferences demonstrates that some individuals place a greater emphasis on short-term outcomes over long-term ones. 17 Thus, the aim of this analysis was to provide objective comparative data on post-treatment mortality to aid patients and providers when weighing treatment options for earlystage NSCLC.
In the largest analysis to date of post-treatment mortality in early-stage NSCLC, we observed moderate increases in absolute mortality with surgery over SBRT at both 30 and 90 days, with larger differences among patients older than 70 years. A comparison of propensity score-matched surgical and SBRT cohorts with balanced sociodemographic, facility-specific, and clinical factors also demonstrated an increase in post-treatment mortality among patients undergoing surgery. These observations are Although surgery was associated with only moderate increases in absolute mortality overall, the most clinically meaningful observations from this analysis are likely related to the significant interaction between older age and increasing post-treatment mortality differences between surgery and SBRT. In particular, the increasing absolute and relative mortality rates with surgery compared to SBRT among patients 71-75, 76-80, and . 80 years of age may have direct implications on shared decision making for elderly patients who are considered higher risk surgical candidates. These data corroborate dedicated surgical series showing an increase in postoperative morbidity and mortality in older age groups, 5,18-21 while also building on those observations by demonstrating a relative increase in the hazard of mortality with surgery compared to SBRT with increasing age and extent of resection (Figures 2 and 3) .
Post-treatment mortality rates were higher after surgery versus SBRT within most age groups in our study, with the exception of the youngest cohorts, which notably included much smaller numbers of patients treated with SBRT (Table 1 ). This latter finding may reflect an unfavorable subgroup of young patients who were poor surgical candidates and were therefore dispositioned to SBRT, which national guidelines consider 
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Increased mortality with SBRT Increased mortality with surgery jco.org a secondary treatment option for early-stage NSCLC. 2, 3 This potential explanation is supported by the observation that the 30-day mortality rate of the youngest SBRT group (age # 55) paradoxically exceeds that of all older groups and that the 90-day rate for this group exceeds that of all but the oldest two groups.
The observed differences in mortality also varied by surgical approach, with risk increasing with surgical complexity, which is consistent with recent large series. 5, 18 With the aforementioned exception of the youngest groups, mortality at both 30 and 90 days after treatment was greater after each surgical resection approach (sublobar resection, lobectomy, and pneumonectomy) than after SBRT. Even patients undergoing sublobar resection, the least extensive surgical procedure that spares the greatest amount of native lung, tended to experience greater mortality than those undergoing SBRT. Mortality rates were highest among patients receiving pneumonectomy, consistent with its established elevated perioperative risk. 22 On MVA, each surgical approach was independently associated with significantly increased risk of mortality at both 30 and 90 days compared to SBRT.
In the contemporary early-stage NSCLC literature, 30-day mortality rates after surgical resection have ranged from 0.7% to . 5%, averaging around 2.5%, and 90-day rates have ranged from 1.2% to . 9%, averaging around 4% to 4.5%. 5, 18, 20, 21, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] These rates tend to be higher in the setting of advanced age and more extensive resections and lower when surgeries are performed under the care of high-volume surgeons and at academic centers. 22 The absolute rates of surgical mortality in this NCDB surgical cohort of 2.07% at 30 days and 3.59% at 90 days are, therefore, slightly improved compared to general estimates from the literature. This finding is encouraging and may be a reflection of the contemporary study interval and the collection of data from ACS-accredited centers in the NCDB rather than from the general population.
In comparison, the corresponding mortality rates observed in our SBRT cohort of 0.73% at 30 days and 2.93% at 90 days well exceeded rates in the literature, which are generally reported to be , 1% in contemporary series, [34] [35] [36] [37] [38] [39] but can be higher in the setting of centrally located tumors. 40 This greater-than-expected mortality after SBRT may be related to a potential increase in the effect of indication bias in a registry dataset, where operable patients preferentially receive surgery, as compared to dedicated SBRT studies. Although consistent with consensus guidelines, [1] [2] [3] this disposition allocates a particular group of patients away from surgery and toward SBRT. Medically inoperable NSCLC patients typically have risk factors, such as advanced age, compromised pulmonary function, impaired cardiovascular fitness, or poor performance status, which increase their operative risk. At baseline, therefore, our surgical and SBRT cohorts exhibit different risk profiles, which constitute the primary limitation of this retrospective analysis. These baseline prognostic differences between medically operable and inoperable patients can translate into widely different outcomes, even when both groups receive the same intervention. 41 The issue of prognostic disparities underscores the importance of completing adequately powered randomized trials comparing surgery and SBRT for patients with early-stage NSCLC.
Strengths of our analysis include a focus on the early posttreatment period, a large study population, a direct comparison of patients across the same institutional pool and time period, and dedicated analyses of outcomes by age and extent of surgical resection. Our study complements the existing body of early-stage NSCLC literature by providing real-world evidence that may be relevant for patients ineligible for randomized trials, 42 particularly those who are older or at a higher risk of post-treatment mortality. Moreover, in providing concrete, age-specific mortality estimates, this analysis may facilitate more informed shared decision-making discussions between patients and providers.
Among the chief limitations of using nonrandomized data to conduct comparative effectiveness analyses is the introduction of selection bias, wherein unbalanced baseline factors can confound observational outcomes, even after statistical adjustment for other known cofactors. Although, even allowing for the effects of selection bias, it is informative that the cohort in our study with the presumed better prognosis on the basis of baseline factors (ie, patients undergoing surgery) were found to have higher rates of post-treatment mortality than a cohort enriched for medically inoperable patients with presumably worse prognosis (ie, patients undergoing SBRT). It is also noteworthy that these mortality differences grew in magnitude when we attempted to adjust for known baseline factors using both multivariate adjustment and PSM. Nevertheless, because neither MVA nor PSM is able to account for differences in unknown variables, the true differences in the hazards of post-treatment mortality after surgery compared with SBRT are likely to be larger than the differences observed in this analysis.
Aside from selection bias, there are a several additional limitations of this analysis. First, the NCDB does not capture data regarding disease control or disease-free survival, each of which would be relevant in the shared decision-making process. Data on quality of life, treatment morbidity, and nonfatal medical events are also unavailable. We were unable to control for smoking status, baseline pulmonary function, cardiovascular fitness, or performance status (including American Society of Anesthesiology physical status classification), each of which is an important factor in treatment selection. Nor could we determine the use of minimally invasive surgical techniques, such as video-assisted thoracoscopic surgical resection. In addition, we analyzed patients diagnosed from 2004 through 2013, a period during which both technology and physician experience with SBRT for early-stage NSCLC progressed. 43, 44 Finally, although data regarding cause of death are not available in the NCDB and are instead limited to allcause mortality, we presumed that most of the observed deaths in our cohort of patients with early-stage NSCLC were secondary to noncancer causes, because cancer-related deaths have historically not contributed significantly to early post-treatment mortality. 4, 5, 37, [45] [46] [47] In conclusion, this analysis demonstrated moderate differences in 30-and 90-day post-treatment mortality between surgery and SBRT that increased as a function of age, with the largest differences observed in patients over 70 years. These data may inform shared decision-making between providers and patients with early-stage NSCLC, particularly those with advanced age or at a high risk of perioperative mortality. jco.org
